Impaired Glucose Tolerance and Insulin Resistance Are Associated With Increased Adipose 11β-Hydroxysteroid Dehydrogenase Type 1 Expression and Elevated Hepatic 5α-Reductase Activity
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—The precise molecular mechanisms contributing to the development of insulin resistance, impaired glucose tolerance (IGT), and type 2 diabetes are largely unknown. Altered endogenous glucocorticoid metabolism, including 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which generates active cortisol from cortisone, and 5α-reductase (5αR), which inactivates cortisol, has been implicated. RESEARCH DESIGN AND METHODS—A total of 101 obese patients (mean age 48 ± 7 years, BMI 34.4 ± 4.3 kg/m2, 66 women, 35 men) underwent 75-g oral glucose tolerance testing (OGTT), body composition analysis (dual-energy X-ray absorptiometry), assessment of glucocorticoid metabolism (24-h urine steroid metabolite analysis by gas chromatography/mass spectrometry), and subcutaneous abdominal adipose tissue biopsies. RESULTS—A total of 22.7% of women had IGT compared with 34.2% of men. Two women and five men were diagnosed with type 2 diabetes. In women, adipose 11β-HSD1 expression was increased in patients with IGT and correlated with glucose levels across the OGTT (R = 0.44, P < 0.001) but was independent of fat mass. Total glucocorticoid secretion was higher in men with and without IGT (normal 13,743 ± 863 vs. 7,453 ± 469 μg/24 h, P < 0.001; IGT 16,871 ± 2,113 vs. 10,133 ± 1,488 μg/24 h, P < 0.05), and in women, it was higher in those with IGT (7,453 ± 469 vs. 10,133 ± 1,488 μg/24 h, P < 0.001). In both sexes, 5αR activity correlated with fasting insulin (men R = 0.53, P = 0.003; women R = 0.33, P = 0.02), insulin secretion across an OGTT (men R = 0.46, P = 0.01; women R = 0.40, P = 0.004), and homeostasis model assessment of insulin resistance (men R = 0.52, P = 0.004; women R = 0.33, P = 0.02). CONCLUSIONS—Increased adipose 11β-HSD1 expression in women may contribute to glucose intolerance. Enhanced 5αR activity in both sexes is associated with insulin resistance but not body composition. Augmented glucocorticoid inactivation may serve as a compensatory, protective mechanism to preserve insulin sensitivity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 2×
“1 mmol/l after 75-g oral glucose testing (OGTT), significantly increases the risk of progression to type 2 diabetes (7), and although rates of progression to type 2 diabetes are variable, they may exceed 10% per year (8,9).”
BackgroundUse and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114 · cited 1×
“Calculated measures of pancreatic -cell function and insulin resistance were made using the homeostasis model assessment (HOMA) 2 model (23).”
MethodWeight gain as a risk factor for clinical diabetes mellitus in women
Colditz, G. A., Willett, W. C., Rotnitzky, A., & Manson, J. E. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-7-199504010-00001 · Cited by 2,064
Obesity, Fat Distribution, and Weight Gain as Risk Factors for Clinical Diabetes in Men
Chan, J. M., Rimm, E. B., Colditz, G. A., Stampfer, M. J., & Willett, W. C. (1994) · Diabetes Care · doi:10.2337/diacare.17.9.961 · Cited by 1,808 · cited 1×
“The association between insulin resistance and obesity almost certainly explains the dramatic relationship between obesity and type 2 diabetes (5,6).”
BackgroundLegro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743
Steroid 5α-reductase: two genes/two enzymes
Russell, D. W., & Wilson, J. D. (1994) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.63.070194.000325 · Cited by 1,105 · cited 1×
“5 R1 is expressed in skin and adipose tissue (18,19) and 5 R2 in prostate, epididymis, and seminal vesicles; both isozymes are expressed in the liver (18).”
Background11β-Hydroxysteroid dehydrogenase type 1: a tissue specific regulator of glucocorticoid response
Tomlinson, J. W., Walker, E. A., Bujalska, I. J., Draper, N., Lavery, G. G., Cooper, M. S., Hewison, M., & Stewart, P. M. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0031 · Cited by 969
Self-citationGerstein, H. C., Santaguida, P., Raina, P., Morrison, K. M., Balion, C., Hunt, D., Yazdi, H., & Booker, L. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.05.004 · Cited by 575
Stewart, P. M., Boulton, A., Kumar, S., Clark, P. M. S., & Shackleton, C. H. L. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.3.5538 · Cited by 398
Self-citationUrinary free cortisone and the assessment of 11β‐hydroxysteroid dehydrogenase activity in man
Palermo, M., Shackleton, C. H. L., Mantero, F., & Stewart, P. M. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.00853.x · Cited by 276 · cited 3×
“Urinary corticosteroid metabolite analysis was performed by gas chromatography/mass spectrometry (GC/MS) as described previously (20).”
BackgroundMethodInfluentialSelf-citationHormonal regulation of hormone-sensitive lipase activity and mRNA levels in isolated rat adipocytes.
Slavin, B. G., Ong, J. M., & Kern, P. A. (1994) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41151-4 · Cited by 261
Lindsay, R. S., Wake, D. J., Nair, S., Bunt, J., Livingstone, D. E. W., Permana, P. A., Tataranni, P. A., & Walker, B. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-030017 · Cited by 225 · cited 1×
“Within the sc depot, most studies, although not all have suggested increased expression with indices of obesity (25-29), but relative expression within the intra-abdominal depot remains controversial.”
BackgroundLavery, G. G., Walker, E. A., Draper, N., Jeyasuria, P., Marcos, J., Shackleton, C. H. L., Parker, K. L., White, P. C., & Stewart, P. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512635200 · Cited by 207 · cited 1×
“Decreases in H6PDH expression and activity decrease oxoreductase and increase dehydrogenase activity (12,13).”
BackgroundSelf-citation5 α-reductase activity in polycystic ovary syndrome
Stewart, P. M., Edwards, C. R. W., Shackleton, C. H. L., & Beastall, G. H. (1990) · The Lancet · doi:10.1016/0140-6736(90)90664-q · Cited by 189
Self-citationBujalska, I. J., Draper, N., Michailidou, Z., Tomlinson, J. W., White, P. C., Chapman, K. E., Walker, E. A., & Stewart, P. M. (2005) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.01718 · Cited by 165
Self-citationTsilchorozidou, T., Honour, J. W., & Conway, G. S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030240 · Cited by 155 · cited 1×
“Moreover, within a cohort of patients with PCOS, 5 R activity correlates with insulin resistance (48).”
BackgroundTomlinson, J. W., Finney, J., Hughes, B. A., Hughes, S. V., & Stewart, P. M. (2008) · Diabetes · doi:10.2337/db08-0094 · Cited by 91
Self-citation
Research works printed but not linked: 29
- Willett,WC, Dietz,WH, Colditz,GA: Guidelines for healthy weight. N Engl J Med 341: 427–434, 1999 · DOI · Paper page
- Lann D, LeRoith D: Insulin resistance as the underlying cause for the metabolic syndrome. Med Clin North Am 91:1063–1077, 2007 · DOI · Paper page
- Fraser R, Ingram MC, Anderson NH, Morrison C, Davies E, Connell JM: Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension 33:1364–1368, 1999 · DOI · Paper page
- Alberts P, Engblom L, Edling N, Forsgren M, Klingstrom G, Larsson C, Ronquist-Nii Y, Ohman B, Abrahmsen L: Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 45:1528–1532, 2002 · DOI · Paper page
- Alberts P, Nilsson C, Selen G, Engblom LO, Edling NH, Norling S, Klingstrom G, Larsson C, Forsgren M, Ashkzari M, Nilsson CE, Fiedler M, Bergqvist E, Eva BB, Abrahmsen LB: Selective inhibition of 11{beta}-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 144:4755–4762, 2003 · DOI · Paper page
- Berthiaume M, Laplante M, Festuccia W, Gelinas Y, Poulin S, Lalonde J, Joanisse DR, Thieringer R, Deshaies Y: Depot-specific modulation of rat intraabdominal adipose tissue lipid metabolism by pharmacological inhibition of 11beta-hydroxysteroid dehydrogenase type 1. Endocrinology 148:2391–2397, 2007 · DOI · Paper page
- Bhat BG, Hosea N, Fanjul A, Herrera J, Chapman J, Thalacker F, Stewart PM, Rejto P: Demonstration of Proof of Mechanism and Pharmacokinetics and Pharmacodynamic Relationship with PF-915275, an Inhibitor of 11{beta}HSD1, in Cynomolgus Monkeys. J Pharmacol Exp Ther 324: 299–305, 2007 · DOI
- Wake DJ, Strand M, Rask E, Westerbacka J, Livingstone DE, Soderberg S, Andrew R, Yki-Jarvinen H, Olsson T, Walker BR: Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesity. Clin Endocrinol (Oxf) 66:440–446, 2007 · DOI · Paper page
- Tomlinson JW, Moore JS, Clark PM, Holder G, Shakespeare L, Stewart PM: Weight loss increases 11beta-hydroxysteroid dehydrogenase type 1 expression in human adipose tissue. J Clin Endocrinol Metab 89:2711–2716, 2004 · DOI · Paper page
- Walker EA, Ahmed A, Lavery GG, Tomlinson JW, Kim SY, Cooper MS, Ride JP, Hughes BA, Shackleton CH, McKiernan P, Elias E, Chou JY, Stewart PM: 11beta-hydroxysteroid dehydrogenase type 1 regulation by intracellular glucose 6-phosphate provides evidence for a novel link between glucose metabolism and hypothalamo-pituitary-adrenal axis function. J Biol Chem 282:27030–27036, 2007 · DOI · Paper page
- Tomlinson JW, Sinha B, Bujalska I, Hewison M, Stewart PM: Expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J Clin Endocrinol Metab 87:5630–5635, 2002 · DOI · Paper page
- Rask E, Olsson T, Soderberg S, Andrew R, Livingstone DE, Johnson O, Walker BR: Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 86:1418–1421, 2001 · doi:10.1210/jcem.86.3.7453 · Paper page
- Rask E, Walker BR, Soderberg S, Livingstone DE, Eliasson M, Johnson O, Andrew R, Olsson T: Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 87:3330–3336, 2002 · DOI · Paper page
- Paulmyer-Lacroix O, Boullu S, Oliver C, Alessi MC, Grino M: Expression of the mRNA coding for 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J Clin Endocrinol Metab 87:2701–2705, 2002 · DOI · Paper page
- Tomlinson JW, Sherlock M, Hughes B, Hughes SV, Kilvington F, Bartlett W, Courtney R, Rejto P, Carley W, Stewart PM: Inhibition of 11{beta}-HSD1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis. J Clin Endocrinol Metab 2007 · DOI · Paper page
- Rigalleau V, Binnert C, Minehira K, Stefanoni N, Schneiter P, Henchoz E, Matzinger O, Cayeux C, Jequier E, Tappy L: In normal men, free fatty acids reduce peripheral but not splanchnic glucose uptake. Diabetes 50:727–732, 2001 · DOI
- Toogood AA, Taylor NF, Shalet SM, Monson JP: Sexual dimorphism of cortisol metabolism is maintained in elderly subjects and is not oestrogen dependent. Clin Endocrinol (Oxf) 52:61–66, 2000 · DOI · Paper page
- Finken MJ, Andrews RC, Andrew R, Walker BR: Cortisol metabolism in healthy young adults: sexual dimorphism in activities of A-ring reductases, but not 11beta-hydroxysteroid dehydrogenases. J Clin Endocrinol Metab 84:3316–3321, 1999 · DOI
- Nwe KH, Hamid A, Morat PB, Khalid BA: Differential regulation of the oxidative 11beta-hydroxysteroid dehydrogenase activity in testis and liver. Steroids 65:40–45, 2000 · DOI
- Ho CK, Tetsuka M, Hillier SG: Regulation of 11beta-hydroxysteroid dehydrogenase isoforms and glucocorticoid receptor gene expression in the rat uterus. J Endocrinol 163:425–431, 1999 · DOI
- Gomez-Sanchez EP, Ganjam V, Chen YJ, Liu Y, Zhou MY, Toroslu C, Romero DG, Hughson MD, de Rodriguez A, Gomez-Sanchez CE: Regulation of 11 beta-hydroxysteroid dehydrogenase enzymes in the rat kidney by estradiol. Am J Physiol Endocrinol Metab 285:E272–E279, 2003 · DOI · Paper page
- Gu S, Ripp SL, Prough RA, Geoghegan TE: Dehydroepiandrosterone affects the expression of multiple genes in rat liver including 11 beta-hydroxysteroid dehydrogenase type 1: a cDNA array analysis. Mol Pharmacol 63:722–731, 2003 · DOI
- Fontbonne A, Thibult N, Eschwege E, Ducimetiere P: Body fat distribution and coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes mellitus: the Paris Prospective Study, 15-year follow-up. Diabetologia 35:464–468, 1992 · DOI
- Can S, Zhu YS, Cai LQ, Ling Q, Katz MD, Akgun S, Shackleton CH, Imperato-McGinley J: The identification of 5 alpha-reductase-2 and 17 beta-hydroxysteroid dehydrogenase-3 gene defects in male pseudohermaphrodites from a Turkish kindred. J Clin Endocrinol Metab 83:560–569, 1998 · DOI
- Andrew R, Phillips DI, Walker BR: Obesity and gender influence cortisol secretion and metabolism in man. J Clin Endocrinol Metab 83:1806–1809, 1998 · doi:10.1210/jcem.83.5.4951 · Paper page
- Andrews RC, Herlihy O, Livingstone DE, Andrew R, Walker BR: Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance. J Clin Endocrinol Metab 87:5587–5593, 2002 · DOI · Paper page
- Stimson RH, Johnstone AM, Homer NZ, Wake DJ, Morton NM, Andrew R, Lobley GE, Walker BR: Dietary macronutrient content alters cortisol metabolism independently of body weight changes in obese men. J Clin Endocrinol Metab 92:4480–4484, 2007 · DOI · Paper page
- Livingstone DE, McInnes KJ, Walker BR, Andrew R: Increased A-ring reduction of glucocorticoids in obese Zucker rats: effects of insulin sensitization. Obes Res 13:1523–1526, 2005 · DOI
- Marberger M: Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia. Nat Clin Pract Urol 3:495–503, 2006 · DOI
Cited by
Pathogenesis of non-alcoholic fatty liver disease
Dowman, J. K., Tomlinson, J. W., & Newsome, P. N. (2010) · QJM · doi:10.1093/qjmed/hcp158 · Cited by 741
Self-citationMechanisms of Glucocorticoid-Induced Insulin Resistance
Geer, E. B., Islam, J., & Buettner, C. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.10.005 · Cited by 392
Morris, M. J., Beilharz, J. E., Maniam, J., Reichelt, A. C., & Westbrook, R. F. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.12.002 · Cited by 285
Minireview: Stress-related psychiatric disorders with low cortisol levels: A metabolic hypothesis
Yehuda, R., & Seckl, J. (2011) · Endocrinology · doi:10.1210/en.2011-1218 · Cited by 276
“This human biology echoes older preclinical literature showing that 5 -reductase is programmed by early-life events in rodents (56, 57) and is particularly influenced by nutritional cues, increasing with high calorie intake/obesity and decreasing with starvation/leanness (58, 59).”
BackgroundFresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions
Li, J.-X., & Cummins, C. L. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00683-6 · Cited by 257
Metadata
- Authors
- Tomlinson, J. W., Finney, J., Gay, C., Hughes, B. A., Hughes, S. V., & Stewart, P. M.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2008-10-01
- Volume
- 57
- Issue
- 10
- Pages
- 2652-2660
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2113828398
- Cited by
- 131
- References
- 18
- FWCI
- 7.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.